Published in Nat Rev Cancer on February 01, 2013
Identification of genomic alterations in oesophageal squamous cell cancer. Nature (2014) 3.10
Integration of tumour and viral genomic characterizations in HBV-related hepatocellular carcinomas. Gut (2014) 2.19
Hepatitis B virus infection and immunopathogenesis in a humanized mouse model: induction of human-specific liver fibrosis and M2-like macrophages. PLoS Pathog (2014) 1.88
Cell death and cell death responses in liver disease: mechanisms and clinical relevance. Gastroenterology (2014) 1.73
Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev Cancer (2013) 1.69
Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma. Nat Immunol (2015) 1.54
Human viral oncogenesis: a cancer hallmarks analysis. Cell Host Microbe (2014) 1.42
Chemopreventive strategies in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol (2013) 1.36
MicroRNA-93 activates c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A. Oncotarget (2015) 1.22
Molecular mechanisms of hepatic apoptosis. Cell Death Dis (2014) 1.21
Molecular mechanism of hepatitis B virus-induced hepatocarcinogenesis. World J Gastroenterol (2014) 1.17
Emerging role of high-mobility group box 1 (HMGB1) in liver diseases. Mol Med (2013) 1.17
LC-MS/MS-based serum proteomics for identification of candidate biomarkers for hepatocellular carcinoma. Proteomics (2015) 1.11
Interleukin-6 (IL-6) and IL-17 synergistically promote viral persistence by inhibiting cellular apoptosis and cytotoxic T cell function. J Virol (2014) 1.08
LC-MS profiling of N-Glycans derived from human serum samples for biomarker discovery in hepatocellular carcinoma. J Proteome Res (2014) 1.08
Small tRNA-derived RNAs are increased and more abundant than microRNAs in chronic hepatitis B and C. Sci Rep (2015) 1.05
Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma. Semin Cancer Biol (2014) 1.04
Circulating miRNA profile in HCV infected serum: novel insight into pathogenesis. Sci Rep (2013) 0.99
Genomic analysis of fibrolamellar hepatocellular carcinoma. Hum Mol Genet (2014) 0.99
HBx-related long non-coding RNA DBH-AS1 promotes cell proliferation and survival by activating MAPK signaling in hepatocellular carcinoma. Oncotarget (2015) 0.99
Cardio-miRNAs and onco-miRNAs: circulating miRNA-based diagnostics for non-cancerous and cancerous diseases. Front Cell Dev Biol (2014) 0.99
Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma. World J Gastroenterol (2015) 0.97
Comparison of hepatocellular carcinoma miRNA expression profiling as evaluated by next generation sequencing and microarray. PLoS One (2014) 0.97
Hepatitis B virus infection is associated with gastric cancer in China: an endemic area of both diseases. Br J Cancer (2015) 0.95
Impact of hepatitis C virus heterogeneity on interferon sensitivity: an overview. World J Gastroenterol (2014) 0.94
The Emerging Role of Nuclear Viral DNA Sensors. J Biol Chem (2015) 0.94
Viruses and human cancers: a long road of discovery of molecular paradigms. Clin Microbiol Rev (2014) 0.93
Towards incorporating epigenetic mechanisms into carcinogen identification and evaluation. Carcinogenesis (2013) 0.92
Association between XPD Lys751Gln and Asp312Asn polymorphisms and hepatocellular carcinoma risk: a systematic review and meta-analysis. Medicine (Baltimore) (2014) 0.90
Replication of genome wide association studies on hepatocellular carcinoma susceptibility loci in a Chinese population. PLoS One (2013) 0.89
Dysregulated signaling hubs of liver lipid metabolism reveal hepatocellular carcinoma pathogenesis. Nucleic Acids Res (2016) 0.89
Molecular alterations in hepatocellular carcinoma associated with hepatitis B and hepatitis C infections. Oncotarget (2016) 0.88
Significance of hepatitis virus infection in the oncogenic initiation of hepatocellular carcinoma. World J Gastroenterol (2016) 0.88
Pseudogene INTS6P1 regulates its cognate gene INTS6 through competitive binding of miR-17-5p in hepatocellular carcinoma. Oncotarget (2015) 0.88
Substrate cleavage profiling suggests a distinct function of Bacteroides fragilis metalloproteinases (fragilysin and metalloproteinase II) at the microbiome-inflammation-cancer interface. J Biol Chem (2013) 0.88
Critical role for the long non-coding RNA AFAP1-AS1 in the proliferation and metastasis of hepatocellular carcinoma. Tumour Biol (2016) 0.88
COX-2-765G>C polymorphism increases the risk of cancer: a meta-analysis. PLoS One (2013) 0.87
Hepatitis B virus therapy: What's the future holding for us? World J Gastroenterol (2015) 0.86
TGF-β signal shifting between tumor suppression and fibro-carcinogenesis in human chronic liver diseases. J Gastroenterol (2013) 0.86
Transcriptomic Analysis of Chronic Hepatitis B and C and Liver Cancer Reveals MicroRNA-Mediated Control of Cholesterol Synthesis Programs. MBio (2015) 0.85
Degradation of miR-21 induces apoptosis and inhibits cell proliferation in human hepatocellular carcinoma. Cancer Gene Ther (2015) 0.85
Protein MRI contrast agent with unprecedented metal selectivity and sensitivity for liver cancer imaging. Proc Natl Acad Sci U S A (2015) 0.84
Immune-based Therapy Clinical Trials in Hepatocellular Carcinoma. J Clin Cell Immunol (2015) 0.84
Occult hepatitis B virus and hepatocellular carcinoma. World J Gastroenterol (2014) 0.84
Oxidative Stress and Liver Cancer: Etiology and Therapeutic Targets. Oxid Med Cell Longev (2016) 0.83
CD81-receptor associations--impact for hepatitis C virus entry and antiviral therapies. Viruses (2014) 0.83
Reversible phospho-Smad3 signalling between tumour suppression and fibrocarcinogenesis in chronic hepatitis B infection. Clin Exp Immunol (2014) 0.83
MICA SNPs and the NKG2D system in virus-induced HCC. J Gastroenterol (2014) 0.83
The Complex Relationship between Liver Cancer and the Cell Cycle: A Story of Multiple Regulations. Cancers (Basel) (2014) 0.82
Control of oxidative stress in hepatocellular carcinoma: Helpful or harmful? World J Hepatol (2015) 0.82
Dynamic imbalance between cancer cell subpopulations induced by transforming growth factor beta (TGF-β) is associated with a DNA methylome switch. BMC Genomics (2014) 0.82
Promotion of Cancer Stem-Like Cell Properties in Hepatitis C Virus-Infected Hepatocytes. J Virol (2015) 0.81
Hepatitis B and C virus-induced hepatitis: Apoptosis, autophagy, and unfolded protein response. World J Gastroenterol (2015) 0.81
Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma. Oncotarget (2015) 0.81
The role of chemokines in hepatitis C virus-mediated liver disease. Int J Mol Sci (2014) 0.81
Hepatocellular carcinoma mouse models: Hepatitis B virus-associated hepatocarcinogenesis and haploinsufficient tumor suppressor genes. World J Gastroenterol (2016) 0.81
Interactions of Hepatitis B Virus Infection with Nonalcoholic Fatty Liver Disease: Possible Mechanisms and Clinical Impact. Dig Dis Sci (2015) 0.81
The immune response in cancer: from immunology to pathology to immunotherapy. Virchows Arch (2015) 0.80
Diffusion of information throughout the host interactome reveals gene expression variations in network proximity to target proteins of hepatitis C virus. PLoS One (2014) 0.80
Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis? World J Gastrointest Oncol (2016) 0.80
Associations of miR-499 and miR-34b/c Polymorphisms with Susceptibility to Hepatocellular Carcinoma: An Evidence-Based Evaluation. Gastroenterol Res Pract (2013) 0.80
Antiviral activities of Indonesian medicinal plants in the East Java region against hepatitis C virus. Virol J (2013) 0.80
Epithelial-to-mesenchymal plasticity of cancer stem cells: therapeutic targets in hepatocellular carcinoma. J Hematol Oncol (2016) 0.80
Regulation of the expression of the liver cancer susceptibility gene MICA by microRNAs. Sci Rep (2013) 0.80
CUL4A facilitates hepatocarcinogenesis by promoting cell cycle progression and epithelial-mesenchymal transition. Sci Rep (2015) 0.80
Liver Monocytes and Kupffer Cells Remain Transcriptionally Distinct during Chronic Viral Infection. PLoS One (2016) 0.80
The transcription factor c-JUN/AP-1 promotes HBV-related liver tumorigenesis in mice. Cell Death Differ (2015) 0.79
Mobile elements and viral integrations prompt considerations for bacterial DNA integration as a novel carcinogen. Cancer Lett (2014) 0.79
Full-length single-cell RNA-seq applied to a viral human cancer: applications to HPV expression and splicing analysis in HeLa S3 cells. Gigascience (2015) 0.79
Metabolic reprogramming: a hallmark of viral oncogenesis. Oncogene (2015) 0.79
Aberrant expression of melanoma-associated antigen-D2 serves as a prognostic indicator of hepatocellular carcinoma outcome following curative hepatectomy. Oncol Lett (2014) 0.79
Identification of characteristic TRB V usage in HBV-associated HCC by using differential expression profiling analysis. Oncoimmunology (2015) 0.79
Radiomics and circulating tumor cells: personalized care in hepatocellular carcinoma? Diagn Interv Radiol (2015) 0.79
Multifunctional DDX3: dual roles in various cancer development and its related signaling pathways. Am J Cancer Res (2016) 0.79
Characterization of monocarboxylate transporter activity in hepatocellular carcinoma. World J Gastroenterol (2014) 0.79
New horizon for radical cure of chronic hepatitis B virus infection. World J Hepatol (2016) 0.79
In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir. Antimicrob Agents Chemother (2017) 0.79
Neuropilin-2 induced by transforming growth factor-β augments migration of hepatocellular carcinoma cells. BMC Cancer (2015) 0.78
Using multiple cytokines to predict hepatocellular carcinoma recurrence in two patient cohorts. Br J Cancer (2013) 0.78
Rapid and quantitative detection of hepatitis B virus. World J Gastroenterol (2015) 0.78
Regulation of gene expression in HBV- and HCV-related hepatocellular carcinoma: integrated GWRS and GWGS analyses. Int J Clin Exp Med (2014) 0.78
Hepatitis B virus PreS2-mutant large surface antigen activates store-operated calcium entry and promotes chromosome instability. Oncotarget (2016) 0.78
Aberrant DNA methylation of imprinted loci in hepatocellular carcinoma and after in vitro exposure to common risk factors. Clin Epigenetics (2015) 0.78
Understanding the interaction of hepatitis C virus with host DEAD-box RNA helicases. World J Gastroenterol (2014) 0.78
Association of Ghrelin Gene Polymorphisms and Serum Ghrelin Levels with the Risk of Hepatitis B Virus-Related Liver Diseases in a Chinese Population. PLoS One (2015) 0.78
Meta-analysis of DNA methylation biomarkers in hepatocellular carcinoma. Oncotarget (2016) 0.77
Up-regulation of BRCA1-associated RING Domain 1 Promotes Hepatocellular Carcinoma Progression by Targeting Akt Signaling. Sci Rep (2017) 0.77
Telomerase reverse transcriptase promoter mutations in hepatitis B virus-associated hepatocellular carcinoma. Oncotarget (2016) 0.77
Association of 5-methylcytosine and 5-hydroxymethylcytosine with mitochondrial DNA content and clinical and biochemical parameters in hepatocellular carcinoma. PLoS One (2013) 0.77
Inhibition of hepatitis B virus gene expression and replication by hepatocyte nuclear factor 6. J Virol (2015) 0.77
Antiviral therapies for hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol (2015) 0.77
Inflammation, cytokines, the IL-17/IL-6/STAT3/NF-κB axis, and tumorigenesis. Drug Des Devel Ther (2015) 0.77
Exploitation of host clock gene machinery by hepatitis viruses B and C. World J Gastroenterol (2013) 0.77
High-throughput T cell receptor sequencing reveals distinct repertoires between tumor and adjacent non-tumor tissues in HBV-associated HCC. Oncoimmunology (2016) 0.77
Successful resection of intracranial metastasis of hepatocellular carcinoma. Case Rep Gastroenterol (2013) 0.77
Significance of viral status on occurrence of hepatitis B-related hepatocellular carcinoma. World J Gastroenterol (2014) 0.77
Exploring the Therapeutic Potentials of iNKT Cells for Anti-HBV Treatment. Pathogens (2014) 0.77
Promoter hypermethylation of Wnt pathway inhibitors in hepatitis C virus - induced multistep hepatocarcinogenesis. Virol J (2014) 0.77
Hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy. World J Gastroenterol (2013) 0.77
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell (2008) 46.08
Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology (2007) 26.78
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature (2009) 26.47
Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell (2008) 14.80
Hepatitis B virus infection. N Engl J Med (1997) 14.50
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature (2009) 13.99
An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science (1996) 13.87
Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet (1981) 13.54
Diagnosis, management, and treatment of hepatitis C. Hepatology (2004) 11.62
Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer (2006) 11.22
Tumour biology: senescence in premalignant tumours. Nature (2005) 10.15
Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol (2005) 9.00
Autophagy is activated for cell survival after endoplasmic reticulum stress. Mol Cell Biol (2006) 8.89
The hepatitis B virus. Nature (1985) 8.71
Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med (2001) 8.47
The Snail genes as inducers of cell movement and survival: implications in development and cancer. Development (2005) 8.42
Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology (2004) 8.36
Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity (1996) 8.27
Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci U S A (1987) 8.11
TGF-beta-induced epithelial to mesenchymal transition. Cell Res (2009) 7.88
Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci U S A (2005) 6.64
Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA. Nature (2008) 6.25
Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science (1999) 6.21
Molecular targeted therapies in hepatocellular carcinoma. Hepatology (2008) 6.16
Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature (2011) 6.14
Hypoxia-inducible factors, stem cells, and cancer. Cell (2007) 5.96
EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology (2008) 5.53
An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell (2008) 5.47
Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res (2007) 5.40
Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem (2007) 5.37
The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist (2010) 4.68
Wnt/β-catenin signaling regulates telomerase in stem cells and cancer cells. Science (2012) 4.51
EMT: when epithelial cells decide to become mesenchymal-like cells. J Clin Invest (2009) 4.41
WNT signaling pathway and stem cell signaling network. Clin Cancer Res (2007) 4.24
EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res (2008) 4.17
Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut (2001) 4.12
Tumour suppression by p53: a role for the DNA damage response? Nat Rev Cancer (2009) 4.06
Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology (2009) 3.92
Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest (2009) 3.80
Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc Natl Acad Sci U S A (1994) 3.76
MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest (2012) 3.46
Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann Surg (2001) 3.25
Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells (2009) 3.25
Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest (2012) 3.14
Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy. N Engl J Med (1991) 3.14
Interaction between beta-catenin and HIF-1 promotes cellular adaptation to hypoxia. Nat Cell Biol (2007) 3.11
The autophagy machinery is required to initiate hepatitis C virus replication. Proc Natl Acad Sci U S A (2009) 2.91
Targeted therapies for hepatocellular carcinoma. Gastroenterology (2011) 2.85
Activation of the unfolded protein response and autophagy after hepatitis C virus infection suppresses innate antiviral immunity in vitro. J Clin Invest (2010) 2.68
Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res (2007) 2.63
Regulation of hepatitis C virus translation and infectious virus production by the microRNA miR-122. J Virol (2010) 2.51
Hepatitis C viral protein NS5A induces EMT and participates in oncogenic transformation of primary hepatocyte precursors. J Hepatol (2012) 2.51
Hepatitis B virus HBx protein activates Ras-GTP complex formation and establishes a Ras, Raf, MAP kinase signaling cascade. Proc Natl Acad Sci U S A (1994) 2.47
Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology (2009) 2.43
Control of cccDNA function in hepatitis B virus infection. J Hepatol (2009) 2.41
Human embryonic genes re-expressed in cancer cells. Oncogene (2001) 2.26
Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway. J Virol (1999) 2.24
Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. J Viral Hepat (2009) 2.18
Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver Dis (2005) 2.18
Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol (2005) 2.13
A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology (2011) 2.08
Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA (2008) 1.94
Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol (2010) 1.93
Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response. J Virol (2001) 1.92
Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology (2005) 1.90
Epithelial-mesenchymal transition in hepatocellular carcinoma. Future Oncol (2009) 1.85
Hepatitis B viral HBx induces matrix metalloproteinase-9 gene expression through activation of ERK and PI-3K/AKT pathways: involvement of invasive potential. FASEB J (2004) 1.84
Embryonic stem cell markers expression in cancers. Biochem Biophys Res Commun (2009) 1.84
Down-regulated microRNA-152 induces aberrant DNA methylation in hepatitis B virus-related hepatocellular carcinoma by targeting DNA methyltransferase 1. Hepatology (2010) 1.81
Hepatitis B: an important public health issue. J Med Virol (2000) 1.81
Expression and gene polymorphisms of interleukin 28B and hepatitis B virus infection in a Chinese Han population. Liver Int (2011) 1.70
Isolation and characterization of hepatic cancer cells with stem-like properties from hepatocellular carcinoma. J Gastrointestin Liver Dis (2010) 1.70
Hepatitis B virus integration, fragile sites, and hepatocarcinogenesis. Cancer Lett (2006) 1.66
Hepatitis B virus HBx protein activates transcription factor NF-kappaB by acting on multiple cytoplasmic inhibitors of rel-related proteins. J Virol (1996) 1.65
Bim-mediated deletion of antigen-specific CD8 T cells in patients unable to control HBV infection. J Clin Invest (2008) 1.62
Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology (2009) 1.59
Direct contribution of epithelium to organ fibrosis: epithelial-mesenchymal transition. Hum Pathol (2009) 1.52
Epithelial cell adhesion molecule regulation is associated with the maintenance of the undifferentiated phenotype of human embryonic stem cells. J Biol Chem (2010) 1.52
Hepatitis B virus X gene and hepatocarcinogenesis. J Gastroenterol (2011) 1.49
IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection. J Infect Dis (2010) 1.48
Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B. Hepatology (2004) 1.46
Hypercytolytic activity of hepatic natural killer cells correlates with liver injury in chronic hepatitis B patients. Hepatology (2010) 1.45
Emerging epigenetic targets and therapies in cancer medicine. Cancer Discov (2012) 1.43
Subversion of cellular autophagy machinery by hepatitis B virus for viral envelopment. J Virol (2011) 1.41
Liver extracellular matrix in health and disease. J Pathol (2003) 1.40
Epigenetic reprogramming and post-transcriptional regulation during the epithelial-mesenchymal transition. Trends Genet (2012) 1.39
Hepatocellualar carcinoma serum markers. Semin Oncol (2012) 1.39
Novel therapeutic strategies for targeting liver cancer stem cells. Int J Biol Sci (2011) 1.39
Hepatitis B virus (HBV) and hepatitis C virus (HCV) dual infection. Int J Med Sci (2006) 1.33
Liver cancer-derived hepatitis C virus core proteins shift TGF-beta responses from tumor suppression to epithelial-mesenchymal transition. PLoS One (2009) 1.33
Regulation of transforming growth factor-beta 1 expression by the hepatitis B virus (HBV) X transactivator. Role in HBV pathogenesis. J Clin Invest (1996) 1.33
Does the hepatitis B antigen HBx promote the appearance of liver cancer stem cells? Cancer Res (2011) 1.33
Hypoxia and hypoxia inducible factors in cancer stem cell maintenance. Curr Top Microbiol Immunol (2010) 1.32
Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): an emerging field for advanced technologies. J Hepatol (2011) 1.30
Hepatitis B virus X protein enhances transcriptional activity of hypoxia-inducible factor-1alpha through activation of mitogen-activated protein kinase pathway. J Biol Chem (2003) 1.29
Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells. J Hepatol (2012) 1.28
Activation and inhibition of cellular calcium and tyrosine kinase signaling pathways identify targets of the HBx protein involved in hepatitis B virus replication. J Virol (2003) 1.28
Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma. Clin Gastroenterol Hepatol (2008) 1.26
Oxidative stress and antioxidants in hepatic pathogenesis. World J Gastroenterol (2010) 1.40
Does the hepatitis B antigen HBx promote the appearance of liver cancer stem cells? Cancer Res (2011) 1.33
Role of miR-148a in hepatitis B associated hepatocellular carcinoma. PLoS One (2012) 1.15
Tupaia CD81, SR-BI, claudin-1, and occludin support hepatitis C virus infection. J Virol (2010) 1.10
Preclinical characterization of GLS4, an inhibitor of hepatitis B virus core particle assembly. Antimicrob Agents Chemother (2013) 1.08
Hepatitis Bx antigen stimulates expression of a novel cellular gene, URG4, that promotes hepatocellular growth and survival. Neoplasia (2002) 1.06
Enhanced cell survival of Hep3B cells by the hepatitis B x antigen effector, URG11, is associated with upregulation of beta-catenin. Hepatology (2006) 0.99
Hedgehog signaling blockade delays hepatocarcinogenesis induced by hepatitis B virus X protein. Cancer Res (2012) 0.96
Mutations in the C-terminus of the X protein of hepatitis B virus regulate Wnt-5a expression in hepatoma Huh7 cells: cDNA microarray and proteomic analyses. Carcinogenesis (2008) 0.94
Preneoplastic markers of hepatitis B virus-associated hepatocellular carcinoma. Cancer Res (2004) 0.93
Hepatitis B x antigen up-regulates vascular endothelial growth factor receptor 3 in hepatocarcinogenesis. Hepatology (2007) 0.89
Hepatitis B virus X protein mutants exhibit distinct biological activities in hepatoma Huh7 cells. Biochem Biophys Res Commun (2008) 0.89
Human S15a expression is upregulated by hepatitis B virus X protein. Mol Carcinog (2004) 0.88
Potent cell growth inhibitory effects in hepatitis B virus X protein positive hepatocellular carcinoma cells by the selective cyclooxygenase-2 inhibitor celecoxib. Mol Carcinog (2009) 0.87
Hepatitis C virus targets over-expression of arginase I in hepatocarcinogenesis. Int J Cancer (2009) 0.87
Hepatitis C virus replication in stably transfected HepG2 cells promotes hepatocellular growth and tumorigenesis. J Cell Physiol (2004) 0.87
Increased expression of ErbB-2 in liver is associated with hepatitis B x antigen and shorter survival in patients with liver cancer. Int J Cancer (2009) 0.86
Putative roles of hepatitis B x antigen in the pathogenesis of chronic liver disease. Cancer Lett (2009) 0.86
Hepatitis B virus X antigen promotes transforming growth factor-beta1 (TGF-beta1) activity by up-regulation of TGF-beta1 and down-regulation of alpha2-macroglobulin. J Gen Virol (2004) 0.84
UCN-01 induces S and G2/M cell cycle arrest through the p53/p21(waf1) or CHK2/CDC25C pathways and can suppress invasion in human hepatoma cell lines. BMC Cancer (2013) 0.83
The hepatitis B x antigen effector, URG7, blocks tumour necrosis factor alpha-mediated apoptosis by activation of phosphoinositol 3-kinase and beta-catenin. J Gen Virol (2007) 0.83
Hepatitis B virus X antigen (HBxAg) and cell cycle control in chronic infection and hepatocarcinogenesis. Front Biosci (2005) 0.81
Adenoviral-mediated RNA interference targeting URG11 inhibits growth of human hepatocellular carcinoma. Int J Cancer (2010) 0.80
Transient inhibition of Th1-type cytokine production by CD4 T cells in hepatitis B core antigen immunized mice is mediated by regulatory T cells. Immunology (2006) 0.79
Upregulated expression of a unique gene by hepatitis B x antigen promotes hepatocellular growth and tumorigenesis. Neoplasia (2003) 0.79
Evaluation of single and combination therapies with tenofovir disoproxil fumarate and emtricitabine in vitro and in a robust mouse model supporting high levels of hepatitis B virus replication. Antimicrob Agents Chemother (2012) 0.78
A spiroligomer α-helix mimic that binds HDM2, penetrates human cells and stabilizes HDM2 in cell culture. PLoS One (2012) 0.78
c-myc overexpression in hepatocarcinogenesis. Hum Pathol (2004) 0.77
Application of HBx-induced anti-URGs as early warning biomarker of cirrhosis and HCC. Cancer Biomark (2012) 0.77
Different response requirements for IFNgamma production in ELISPOT assays by CD4+ T cells from mice early and late after immunization. J Immunol Methods (2005) 0.77
Detection of hepatitis B virus X antigen by immunohistochemistry and Western blotting. Methods Mol Med (2004) 0.75
[Preneoplastic markers of hepatitis B virus-associated hepatocellular carcinoma and their significance in clinical settings]. Zhonghua Gan Zang Bing Za Zhi (2007) 0.75